Stock Events

Stock Events

CanSino Biologics 

€3.08
0
+€0.04+1.32% Today

Statistics

Day High
3.08
Day Low
3.08
52W High
5.91
52W Low
3.04
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 22
€0.12
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

28AprExpected
Q1 2026
-0.02
0.31
0.65
0.98
Expected EPS
N/A
Actual EPS
-0.019791408912

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CJH.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech competes directly in the development of mRNA vaccines, similar to CanSino's viral vector COVID-19 vaccine.
Moderna
MRNA
Mkt Cap17.99B
Moderna is a leader in mRNA technology for vaccines, directly competing with CanSino's vaccine development approach.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca developed a viral vector COVID-19 vaccine, similar to CanSino, making them direct competitors in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson also developed a viral vector COVID-19 vaccine, competing in the same space as CanSino.
Pfizer
PFE
Mkt Cap149.77B
Pfizer, in collaboration with BioNTech, competes in the vaccine market, particularly with mRNA technology which is a leading approach in vaccine innovation.
Sinovac Biotech
SVA
Mkt Cap642.44M
Sinovac Biotech is another major Chinese biopharmaceutical company that develops vaccines, competing in the same regional market as CanSino.
Novavax
NVAX
Mkt Cap1.32B
Novavax develops vaccines based on protein subunit technology, offering alternative vaccine options and competing in the global vaccine market.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline is a large pharmaceutical company with a broad vaccine portfolio, competing globally with companies like CanSino.
Sanofi
SNY
Mkt Cap110.4B
Sanofi is involved in vaccine development and production, competing in the same market as CanSino with a diverse range of vaccine technologies.

About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Show more...
CEO
Dr. Xuefeng Yu Ph.D.
Employees
1134
Country
China
ISIN
CNE100003F01

Listings

STU
DE
CJH.STU
SHG
CN
688185.SHG
MU
DE
CJH.MU
F
DE
CJH.F

0 Comments

Share your thoughts

FAQ

What is CanSino Biologics stock price today?▼
The current price of CJH.STU is €3.08 EUR — it has increased by +1.32% in the past 24 hours. Watch CanSino Biologics stock price performance more closely on the chart.
What is CanSino Biologics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CanSino Biologics stocks are traded under the ticker CJH.STU.
Is CanSino Biologics stock price growing?▼
CJH.STU stock has fallen by -3.75% compared to the previous week, the month change is a -14.87% fall, over the last year CanSino Biologics has showed a -17.91% decrease.
When is the next CanSino Biologics earnings date?▼
CanSino Biologics is going to release the next earnings report on August 21, 2026.
What were CanSino Biologics earnings last quarter?▼
CJH.STU earnings for the last quarter are -0.02 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does CanSino Biologics pay dividends?▼
Yes, CJH.STU dividends are paid annual. The last dividend per share was 0.12 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does CanSino Biologics have?▼
As of May 06, 2026, the company has 1,134 employees.
In which sector is CanSino Biologics located?▼
CanSino Biologics operates in the Health & Wellness sector.
When did CanSino Biologics complete a stock split?▼
CanSino Biologics has not had any recent stock splits.
Where is CanSino Biologics headquartered?▼
CanSino Biologics is headquartered in Tianjin, China.